- Home
- LZ vs GLPG Comparison
LZ vs GLPG Comparison
Compare LZ & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZ
- GLPG
- Stock Information
- Founded
- LZ 2001
- GLPG 1999
- Country
- LZ United States
- GLPG Belgium
- Employees
- LZ N/A
- GLPG N/A
- Industry
- LZ EDP Services
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- LZ Technology
- GLPG Health Care
- Exchange
- LZ Nasdaq
- GLPG Nasdaq
- Market Cap
- LZ 1.8B
- GLPG 1.8B
- IPO Year
- LZ 2021
- GLPG 2005
- Fundamental
- Price
- LZ $9.17
- GLPG $27.73
- Analyst Decision
- LZ Hold
- GLPG Sell
- Analyst Count
- LZ 9
- GLPG 4
- Target Price
- LZ $8.64
- GLPG $25.33
- AVG Volume (30 Days)
- LZ 1.9M
- GLPG 432.0K
- Earning Date
- LZ 05-07-2025
- GLPG 07-31-2025
- Dividend Yield
- LZ N/A
- GLPG N/A
- EPS Growth
- LZ 72.11
- GLPG N/A
- EPS
- LZ 0.17
- GLPG N/A
- Revenue
- LZ $690,777,000.00
- GLPG $311,493,731.00
- Revenue This Year
- LZ $8.12
- GLPG $0.78
- Revenue Next Year
- LZ $6.66
- GLPG N/A
- P/E Ratio
- LZ $53.57
- GLPG N/A
- Revenue Growth
- LZ 3.25
- GLPG 18.32
- 52 Week Low
- LZ $5.33
- GLPG $22.36
- 52 Week High
- LZ $10.60
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- LZ 56.65
- GLPG 50.32
- Support Level
- LZ $8.91
- GLPG $28.57
- Resistance Level
- LZ $9.66
- GLPG $29.41
- Average True Range (ATR)
- LZ 0.26
- GLPG 0.52
- MACD
- LZ -0.07
- GLPG -0.16
- Stochastic Oscillator
- LZ 31.52
- GLPG 9.33
About LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.